Novo Nordisk accelerates clinical documentation and drug development with Claude
Claude life sciences
Your research partner for rigorous science
Claude works through problems alongside your team and shows its work, from your first hypothesis to the final submission.
Built for breakthroughs
AI you can verify
Claude shows the lowest hallucination rates and is built with biosafety guardrails. When you connect to PubMed, bioRxiv, and research databases, claims are traced to their source, so teams can verify before they act.
Built for scientific complexity
Analyze genomic data, synthesize hundreds of papers, and design experiments. With Opus 4.7, Claude shows notable improvements in biology benchmarks including BioPipelineBench, single-cell RNA analysis, and structural biology.
Made for R&D
Claude can connect to Benchling, PubMed, 10x Genomics, and ClinicalTrials.gov, so every scientist can connect to data for accurate work.
Claude performs at expert level on real bioinformatics problems, sometimes solving them in unexpected ways.
With Opus 4.7, Claude's structural biology reasoning has more than doubled, and it can now read chemical structures, technical diagrams, and complex experimental data.
How life sciences teams use Claude
Bioinformatics analysis
Process genomic data with validated bioinformatics pipelines through Claude Code. Claude connects to 10x Genomics and Benchling, then delivers annotated, reproducible reports you can share with cross-functional teams without needing to provide complex code.
Research synthesis
Survey hundreds of papers in hours instead of weeks. Claude synthesizes findings across PubMed, bioRxiv, and proprietary databases, identifies contradictions, and generates testable hypotheses with verifiable citations tailored to your research questions.
Phase 2 Clinical Trial Protocol
ABX-7291 for Treatment of Parkinson's Disease | DRAFT v0.1
Study Synopsis
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABX-7291 in Patients with Early-Stage Parkinson's Disease
Sponsor: [Sponsor Name]
Phase: Phase 2
Indication: Early-stage Parkinson's Disease (Hoehn & Yahr Stage 1-2)
Study Duration: 24 weeks treatment + 4 weeks follow-up
Objectives and Endpoints
Primary Objective
Evaluate the efficacy of ABX-7291 compared to placebo in reducing motor symptoms in patients with early-stage Parkinson's disease.
Primary Endpoint
Change from baseline in MDS-UPDRS Part III (Motor Examination) score at Week 24.
Secondary Endpoints
- Change from baseline in MDS-UPDRS Total Score at Week 24
- Proportion of patients achieving ≥30% improvement in MDS-UPDRS Part III
- Change in PDQ-39 (Quality of Life) score at Week 24
- Safety and tolerability (AEs, laboratory parameters, vital signs)
Study Design
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study. Eligible patients will be randomized 1:1:1 to receive ABX-7291 low dose, ABX-7291 high dose, or placebo for 24 weeks.
Sample Size and Rationale
Total Enrollment: 120 patients (40 per arm)
Statistical Power: 80% power at α=0.05 (two-sided)
Expected Effect Size: 5-point difference in MDS-UPDRS Part III (SD=8)
Dropout Assumption: 15% (based on comparable Phase 2 PD trials)
Rationale: Sample size derived from analysis of 12 comparable Phase 2 trials on ClinicalTrials.gov with similar indications and endpoints.
Regulatory References
- 21 CFR 312 (Investigational New Drug Application)
- FDA Guidance: Parkinson's Disease: Developing Drugs for Treatment (2023)
- ICH E6(R2): Good Clinical Practice
- ICH E9: Statistical Principles for Clinical Trials
Generated using Clinical Protocol Generation skill
Sources: ClinicalTrials.gov (12 comparable studies), FDA guidance documents
Ready for review with biostatisticians and regulatory affairs
Clinical trial protocols
Draft clinical protocols with built-in regulatory cross-referencing. Claude researches FDA guidances, analyzes comparable trials on ClinicalTrials.gov, and generates structured protocol drafts ready for review with biostatisticians and regulatory affairs.
Clinical Safety Summary
Module 2.7.4 | IND-2024-0892
Study Overview
Drug: ABX-4721 (anti-inflammatory biologic)
Phase: Phase 1
Subjects: 48 healthy volunteers
Duration: 12-week duration
Adverse Event Summary
Total subjects with AEs: 23 (47.9%)
Serious adverse events: 2 (4.2%)
Discontinuations due to AEs: 1 (2.1%)
Deaths: 0
Safety Signals for Phase 2 Monitoring
⚠ Hepatic
Elevated ALT (>3x ULN): 3 subjects (6.3%)
All resolved without intervention within 14 days
→ Recommend: LFT monitoring at weeks 2, 4, 8
⚠ Injection site reactions
Mild erythema: 8 subjects (16.7%)
No treatment required
→ Recommend: Document severity grading in Phase 2
Regulatory References
- 21 CFR 312.32 (IND Safety Reporting)
- ICH E2A: Clinical Safety Data Management
- FDA Guidance: Premarketing Risk Assessment
Generated from uploaded AE reports and lab data
All source documents linked for audit trail

Regulatory affairs
Compile structured submissions from clinical and preclinical data with automatic cross-referencing against FDA guidance. Claude flags gaps in your regulatory package before anything ships.
I'll modernize the pharmacokinetic module. Let me start by understanding the existing FORTRAN code.
Reading the source file...
* pk_compartment.f (847 lines, FORTRAN 77)
* Three-compartment model with IMSL numerical routines
* Last modified 1998
Mapping the dependencies...
* 14 IMSL calls (DIVPRK, LSARG, DGEAR)
* Common blocks for parameter sharing
* Hardcoded clearance constants in the rate equations
Translating the ODE solver to scipy.integrate.solve_ivp and replacing the IMSL routines with NumPy and SciPy equivalents...
Adding type hints, docstrings, and a PKParameters dataclass to replace the common blocks...
Generating pytest cases against the legacy outputs. Validating numerical parity within 1e-6 tolerance...
Modernization complete.
* 23 / 23 tests passing
* Numerical drift below 1e-7
* Reduced from 847 to 312 lines
I'll modernize the pharmacokinetic module. Let me start by understanding the existing FORTRAN code.
Reading the source file...
* pk_compartment.f (847 lines, FORTRAN 77)
* Three-compartment model with IMSL numerical routines
* Last modified 1998
Mapping the dependencies...
* 14 IMSL calls (DIVPRK, LSARG, DGEAR)
* Common blocks for parameter sharing
* Hardcoded clearance constants in the rate equations
Translating the ODE solver to scipy.integrate.solve_ivp and replacing the IMSL routines with NumPy and SciPy equivalents...
Adding type hints, docstrings, and a PKParameters dataclass to replace the common blocks...
Generating pytest cases against the legacy outputs. Validating numerical parity within 1e-6 tolerance...
Modernization complete.
* 23 / 23 tests passing
* Numerical drift below 1e-7
* Reduced from 847 to 312 lines
Legacy code modernization
Build life sciences software faster with Claude Code. Claude helps engineers navigate legacy scientific codebases, write robust code for GxP-regulated environments, and catch compliance issues in PR reviews before they ship.
More products for life sciences
Claude for Microsoft 365
Refine a clinical study in Word, update trial data in Excel, build research presentations in PowerPoint, and do team coordination in Outlook. Claude carries context across it all.
Claude Cowork
Automate routine lab workflows and data processing tasks. Cowork handles repetitive work like data entry and file management so scientists can focus on discovery.
Claude Code
Accelerate bioinformatics pipelines and validate scientific software under GxP requirements. Turn computational biology challenges into working code in minutes.













Claude connects to your research ecosystem
Literature, lab notebooks, and analysis platforms, all working together in one place.
Get started with Claude
Pro
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Access to research
- Access to Claude Code
- Life sciences guides and docs
Max
- Choose 5x or 20x more usage than Pro*
- Higher output limits for all tasks
- Early access to advanced Claude features
Team
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Single sign-on (SSO)
- Central billing and administration
- Includes Claude Code
- Life sciences guides and docs
Enterprise
- More usage*
- HIPAA-ready infrastructure (added cost)
- Enhanced context window
- Compliance API for observability and monitoring
- Single sign-on (SSO) and domain capture
- Custom data retention controls
Usage limits apply. Prices shown don’t include applicable tax. Price and plans are subject to change at Anthropic's discretion.

